what we have to consider in regard to market releases is that immutep have a couple of trials in progress (NSCLC & HNC) that have
been given fast-track status by the FDA.....This ensures closer collaboratation including input from the FDA in regard to trial protocal
that is essential to be followed for fast-track approval should data results and patient response suggest it worthwhile....Marc's duty
to shareholders is to ensure this procedure is compliant and given every chance of success...
what we have to consider in regard to market releases is that...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.035(10.5%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $3.795M | 12.47M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 477550 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 326382 | 18 |
View Market Depth
| Last trade - 11.49am 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |